Browsing: EventFree

Diagnosis

Azacitidine/Venetoclax Boosts Event-Free Survival in Induction-Eligible AML

By NewsCancerSeptember 8, 20260

Azacitidine (Vidaza) plus venetoclax (Venclexta) led to significantly longer event-free survival (EFS) than induction chemotherapy among patients with newly diagnosed…

► Necessary Cookies Always Active

Necessary cookies enable essential site features like secure log-ins and consent preference adjustments. They do not store personal data.

► Functional Cookies Remark

Functional cookies support features like content sharing on social media, collecting feedback, and enabling third-party tools.

► Analytical Cookies Remark

Analytical cookies track visitor interactions, providing insights on metrics like visitor count, bounce rate, and traffic sources.

► Advertisement Cookies Remark

Advertisement cookies deliver personalized ads based on your previous visits and analyze the effectiveness of ad campaigns.

What's Hot

Why MRI Contrast Agents Are Not Interchangeable for Detecting Brain Metastases

INBRX-106 Plus Pembrolizumab Nearly Doubles Response Rate in HNSCC

CD8+ T cells kill tumors by proxy

Browsing: EventFree

Azacitidine/Venetoclax Boosts Event-Free Survival in Induction-Eligible AML

Why MRI Contrast Agents Are Not Interchangeable for Detecting Brain Metastases

INBRX-106 Plus Pembrolizumab Nearly Doubles Response Rate in HNSCC

CD8+ T cells kill tumors by proxy

Paxalisib/Gemcitabine Combination Dosed in First Patient With CNS Tumor

Why MRI Contrast Agents Are Not Interchangeable for Detecting Brain Metastases

INBRX-106 Plus Pembrolizumab Nearly Doubles Response Rate in HNSCC

CD8+ T cells kill tumors by proxy

Paxalisib/Gemcitabine Combination Dosed in First Patient With CNS Tumor

Latest Post

Why MRI Contrast Agents Are Not Interchangeable for Detecting Brain Metastases

INBRX-106 Plus Pembrolizumab Nearly Doubles Response Rate in HNSCC

CD8+ T cells kill tumors by proxy

Subscribe to Updates

What's Hot

Browsing: EventFree